Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Manipulating the gut microbiota to combat alcoholic hepatitis

Alcoholic hepatitis is a severe and life-threatening form of alcohol-associated liver disease (ALD), but few effective therapies are available. Now, new research pinpoints the gut microbiota as an important therapeutic target for ALD, identifying Enterococcus faecalis and the exotoxin that it secretes, cytolysin, as important factors in the development and progression of ALD. Moreover, precise targeting of cytolysin-positive (cytolytic) E. faecalis with bacteriophage treatment attenuated ALD in a mouse model, and could be a promising novel therapeutic approach for patients with ALD.


“The number of people with chronic liver disease is increasing rapidly in Western countries,” explains author Bernd Schnabl. “Liver cirrhosis (end-stage organ disease) is the twelfth leading cause of mortality worldwide; approximately half of these deaths are due to alcohol use disorder,” he adds. A link between the gut microbiota and ALD across the spectrum of disease (from alcoholic fatty liver to alcoholic hepatitis and cirrhosis) had already been demonstrated, but the underlying mechanisms and precise role of microorganisms were unknown. Previous work had shown that ALD could be transferred via faecal microbiota transplantation from patients with alcoholic hepatitis in germ-free mice, and so Schnabl and colleagues wanted to investigate the bacteria and toxins responsible for this transmissible phenotype and their role in ALD development.

First, the investigators examined the gut microbiota in different patient cohorts, and confirmed that chronic alcohol use (n = 44) and alcoholic hepatitis (n = 88) were associated with alterations in the composition of the faecal microbiota compared with individuals without alcohol-use disorders as controls (n = 26). One notable difference was the increased proportion of Enterococcus spp. in patients with alcoholic hepatitis (accounting for 5.59% of faecal bacteria versus almost none identified in faecal bacteria from controls). Moreover, faecal samples from patients with alcoholic hepatitis had ~2,700-fold more E. faecalis than controls, with ~80% of patients with alcoholic hepatitis positive for E. faecalis in faeces. Importantly, the presence of cytolytic E. faecalis correlated with both the severity of liver disease and with mortality in these patients; most cytolysin-positive patients with alcoholic hepatitis (89%) died within 180 days of admission.

Next, the researchers used mouse models of ALD to demonstrate that cytolysin directly promoted disease development. Importantly, cytolysin directly induced hepatocyte death in vitro, and promoted liver injury in the context of ethanol-induced liver disease (chronic-binge ethanol diet) in mice. Mice colonized with cytolytic E. faecalis and then fed ethanol had more severe liver injury and increased hepatic steatosis than controls. The same trend in ALD severity was observed in germ-free mice that received faecal transplants from cytolysin-positive patients with alcoholic hepatitis.

Finally, the researchers developed a novel therapeutic approach using bacteriophages to target cytolytic E. faecalis specifically. In a humanized mouse model of ALD, bacteriophage treatment decreased cytolysin in the liver and abolished ethanol-induced liver injury and steatosis.

“This novel bacteriophage approach might be developed to alter the intestinal microbiomes of and treat patients with alcoholic hepatitis,” says Schnabl. “Phage therapy offers the opportunity to very precisely edit the gut microbiota and selectively target specific, toxin-producing bacterial strains.”

“the presence of cytolytic E. faecalis correlated with both the severity of liver disease and with mortality”

The researchers call for more studies to validate their findings. “An independent cohort of patients with alcoholic hepatitis is required to validate the human relevance of our findings and to test cytolysin as a predictive biomarker,” notes Schnabl, adding that a phase I clinical safety study using bacteriophage therapy in patients with alcoholic hepatitis is necessary to move forwards to the clinic.


Original article

  1. Duan, Y. et al. Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. Nature 575, 505–511 (2019)

    CAS  Article  Google Scholar 

Related article

  1. Bajaj, J. S. Alcohol, liver disease and the gut microbiota. Nat. Rev. Gastroenterol. Hepatol. 16, 235–246 (2019)

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Katrina Ray.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ray, K. Manipulating the gut microbiota to combat alcoholic hepatitis. Nat Rev Gastroenterol Hepatol 17, 3 (2020).

Download citation


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing